Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “sotagliflozin” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 15
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 15 pipeline programs matching "sotagliflozin" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

15 results for “sotagliflozin” Back to intelligence hub

Search results

  1. PLACEBO SOTAGLIFLOZIN, SOTAGLIFLOZIN

    LEXICON PHARMACEUTICALS, INC.

    Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial
  2. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Heart Failure

    phase 3 small molecule terminated

    2 trials
  3. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Nephropathies

    phase 3 small molecule active

    1 trial
  4. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Obstructive Cardiomyopathy, Hypertrophic

    phase 3 small molecule active

    1 trial
  5. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus

    phase 3 small molecule completed

    3 trials
  6. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus (T1DM)

    phase 3 small molecule completed

    1 trial
  7. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials
  8. Sotagliflozin (SAR439954)

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    4 trials
  9. Sotagliflozin Low Dose

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes (T1D)

    phase 3 small molecule active

    1 trial
  10. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes

    phase 2 small molecule active

    2 trials
  11. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Cardiac Failure Aggravated

    phase 2 small molecule terminated

    1 trial
  12. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Renal Impairment

    phase 1 small molecule completed

    1 trial
  13. Sotagliflozin (SOTA) followed by 3 drugs in a random order

    LEXICON PHARMACEUTICALS, INC.

    Platelet Function and Reactivity Tests

    phase 1 small molecule active

    1 trial
  14. sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule active

    1 trial
  15. sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.